UK vows to speed up drug review in return for 2% sales cap 27-Nov-2018 By Ben Hargreaves UK government and ABPI have agreed a deal to limit branded drug sales growth to 2%, potentially reducing the cost of medicine by £930m.
UK invests to streamline manufacture of next-gen medicine 23-Nov-2018 By Ben Hargreaves Funding of £7.3m will be provided across three initiatives, with the long-term aim of providing patients with access to cell and gene therapies at a faster rate.
